Kolexia
Bertoli Sarah Hématologie
Bertoli Sarah
Hématologie
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
170 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie aigüe myéloïde Leucémies Leucémie myéloïde Maladie aigüe Récidive tumorale locale Leucémie-lymphome lymphoblastique à précurseurs B et T Aberrations des chromosomes Maladie résiduelle Syndromes myélodysplasiques

Collaborateurs

Voir plus
Recher Christian
Recher Christian
Hôpital Purpan, Toulouse, France
Delabesse Eric
Delabesse Eric
Oncopole Toulouse, Toulouse, France
Tavitian Suzanne
Tavitian Suzanne
Oncopole Toulouse, Toulouse, France
Huguet Francoise
Huguet Francoise
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

Industries

Voir plus
Abbvie
21 collaboration(s)
Dernière en 2023
KEPHREN PUBLISHING
8 collaboration(s)
Dernière en 2023
BMS
7 collaboration(s)
Dernière en 2023
Amgen
6 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
Cancer medicine   26 février 2024
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
Annals of hematology   26 janvier 2024
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
Leukemia research   09 janvier 2024
Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1-Mutated Acute Myeloid Leukemia - a Filo Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival
65th ASH Annual Meeting Abstracts   02 novembre 2023
Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
65th ASH Annual Meeting Abstracts   02 novembre 2023
Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Tyrosine Kinase Inhibitors with Intensive Chemotherapy in AML with t(9;22)(q34.1;q11.2)/ BCR::ABL1: Time to Reconsider Prognostic Risk? a Study from the Dataml Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Real-World Treatment Patterns and Clinical Outcomes in Newly Diagnosed Acute Myeloid Leukemia with and without mIDH1 Treated with Intensive Chemotherapy from an International Real-World Database (REAL-IDH)
65th ASH Annual Meeting Abstracts   02 novembre 2023